公开(公告)号：US20230393151A1

公开(公告)日：2023-12-07

申请号：US18006212

申请日：2021-07-20

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Scott A. SMALL ,  Sabrina ALVES SIMOES SPASSOV ,  Yasir QURESHI

IPC: G01N33/68 ,  C12N15/86 ,  A61K38/16 ,  A61P25/28 ,  A61P25/16

CPC classification number: G01N33/6896 ,  C12N15/86 ,  A61K38/16 ,  A61P25/28 ,  A61P25/16 ,  G01N2800/2821 ,  G01N2800/2835 ,  C12N2750/14143

Abstract: The present disclosure relates to methods and compositions for elevating and stabilizing retromer protein for treating and/or preventing neurodegenerative diseases and disorders including Alzheimer's disease and Parkinson's disease, where retromer dysfunction and/or endosomal trafficking dysfunction is involved and/or implicated in the disease or disorder. The methods include the use of agents to elevate and stabilize specific retromer depending upon the neurodegenerative disease or disorder being treated. The method can also include the use of one or more biomarkers to detect and/or identify whether retromer dysfunction and/or endosomal trafficking dysfunction is involved and/or implicated in the disease or disorder.

公开(公告)号：US11835803B2

公开(公告)日：2023-12-05

申请号：US17119328

申请日：2020-12-11

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Michal Lipson ,  Janderson Rocha Rodrigues

IPC: G02F1/035

CPC classification number: G02F1/035

Abstract: Methods, devices and systems for communication are disclosed. An example device can comprise a first waveguide portion disposed on a substrate, a second waveguide portion, and a third waveguide portion disposed between the first waveguide portion and the second waveguide portion. The third waveguide portion can be configured to carry a signal based on a refractive index of the third waveguide portion matching an effective refractive index of an optical mode of a combination of the first waveguide portion and the second waveguide portion.

公开(公告)号：US20230382919A1

公开(公告)日：2023-11-30

申请号：US18366544

申请日：2023-08-07

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Dalibor Sames ,  Vaclav Havel ,  Benjamin Bechond ,  David Lankri

IPC: C07D487/18 ,  C07D487/04 ,  C07D491/18 ,  C07D491/048 ,  C07D495/04 ,  C07D495/18

CPC classification number: C07D487/18 ,  C07D487/04 ,  C07D491/18 ,  C07D491/048 ,  C07D495/04 ,  C07D495/18

Abstract: The present invention provides a compound having the structure:






wherein
D, E and F are each independently NR1, CR2R3 or CR6R7,

wherein one of D, E and F is NR1 and the remaining two are CR2R3 or CR6R7,
wherein R1 is H or -(alkyl), and
wherein R2, R3, R6 and R7 are each independently H, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -alkylcycloalkyl, -aryl, heteroaryl or -alkylaryl;


X1 is C or N;
X2 is O, S, N, NR14 or CR15,

wherein R14 is H, -(alkyl) or -cycloalkyl,
wherein R15 is H, -(alkyl) or -cycloalkyl, and
wherein X2 is other than N when X1 is N;


α and β represent a bond that is present or absent, and wherein either α or β is present,

wherein when α is present, then X1 is C and X2 is O, S or NR14, or
when β is present, then X1 is N and X2 is N or CR15;


R4, R5, R8 and R9 are each independently H, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -alkylcycloalkyl, -aryl, heteroaryl, -alkylaryl, —OH, —O(alkyl), —OAc, —S(alkyl), —NH2, —NH(alkyl), —N(alkyl)2, —COOH, —CO2(alkyl), —CONH2, —CONH(alkyl), —CON(alkyl)2 or —CN,

wherein when D is NR1 then R4 and R5 are each independently H, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -alkylcycloalkyl, -aryl, heteroaryl or -alkylaryl,
wherein when F is NR1 then R8 and R9 are each independently H, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -alkylcycloalkyl, -aryl, heteroaryl or -alkylaryl or


R1 and R4 together form a —(CH2)m—, wherein m represents an integer from 2 to 4; and
R10, R11, R12 and R13 are each independently H, halogen, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -(aryl), -(heteroaryl), —OH, —OAc, —O(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(aryl), —O-(heteroaryl), —SH, —S(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —NH-(aryl), —NH-(heteroaryl), —CO2(alkyl), —CONH2, —CN, —CF3, —CF2H, —OCF3 or NO2 or
R10 and R11 together form a —O(CH2)O— or
R11 and R12 together form a —O(CH2)O— or
R12 and R13 together form a —O(CH2)O—;
wherein when X1 is C, X2 is NR14, and D is CR2R3, E is NR1, F is CR6R7, then (i) R14 and at least two of R10, R11, R12 and R13 are other than hydrogen, or (ii) one of R2, R3, R6 and R7 is other than H,
wherein when X1 is C, X2 is O, and E is NH, NCH3, NCH2CH3, or NCH(CH3)2, and one of R10, R11, R12 and R13 is —OCH3 or —SCH3, then (i) one of R2, R3, R4, R5, R6, R7, R8 or R9 is other than H, or (ii) at least two of R10, R11, R12 and R13 are other than H,
wherein when X1 is C, X2 is O, and F is NH, then at least one of R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 or R13 is other than H,
wherein when X1 is C, X2 is S, and R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each H, and R11 is Br, then D and E is other than NH,
wherein when X1 is N, X2 is CR15, D is CR2R3, E is NR1, F is CR6R7, and R1, R2, R3, R4, R5, R6, R7, R8 and R9 are H, and R15 is H, then one of R10, R11, R12 or R13 is other than H, and R10 is other than OMe, R11 is other than Br, R12 is other than Br and Cl, and R13 is other than OMe,
wherein when X1 is N, X2 is CR15, D is CR2R3, E is NR1, F is CR6R7, R1 is alkyl, R2, R3, R4, R5, R6, R7, R8 and R9 are H, and R15 is CH3, then at least one of R10, R11, R12 or R13 is other than H and CH3, and R11 is other than a ketone and a carboxylic acid,
wherein when R1 and R4 together form a —(CH2)3—, X1 is C, X2 is NR14, D is CR2R3, E is NR1, F is CR6R7, and R2, R3, R5, R6, R7, R8, R9, R10, R12, R13 and R14 are each H, then R11 is other than H, F or —CH3,

or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230376115A1

公开(公告)日：2023-11-23

申请号：US18228575

申请日：2023-07-31

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Sean Perkins ,  Mark Churchland ,  Karen Schroeder

IPC: G06F3/01

CPC classification number: G06F3/015 ,  A61B5/372

Abstract: Mechanisms including: receiving a first set of observed spike counts (FSoOSCs) for the spiking cells; determining a set of probabilities (SoPs) by: retrieving the SoPs from stored information (SI); or calculating the SopS based on the SI, wherein the SI regards possible biological states (BSs) of a subject, wherein each of the possible BSs belongs to at least one of a plurality of time sequences (PoTSs) of BSs, wherein each of the PoTSs of BSs corresponds to a possible action of the subject, and wherein each probability in the set of probabilities indicates a likelihood of observing a possible spike count for one of the plurality of spiking cells; identifying using a hardware processor a first identified BS of the subject from the possible BSs based on the FSoOSCs and the set of probabilities; and determining an action to be performed based on the first identified BS.

公开(公告)号：US20230365690A1

公开(公告)日：2023-11-16

申请号：US18040888

申请日：2021-08-08

Applicant: NORTHWESTERN UNIVERSITY ,  THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Inventor： Víctor Andrés Arrieta González ,  Raul Rabadan ,  Fabio M. Iwamoto ,  Adam M. Sonabend Worthalter

IPC: C07K16/28 ,  A61P35/04 ,  A61K45/06 ,  G01N33/574

CPC classification number: C07K16/2818 ,  A61P35/04 ,  A61K45/06 ,  G01N33/57484 ,  G01N2440/14 ,  G01N2333/91205

Abstract: Disclosed herein are methods for identifying subjects, diagnosed as having glioblastoma (GBM), as likely responders to treatment with a programmed death protein 1 (PD-1) blockade. In some embodiments, the subjects are identified by determining the level of phosphorylated extracellular-signal-regulated kinase (p-ERK) in a GBM tumor sample from the subject. In some embodiments, the GBM is recurrent. Also disclosed herein are methods of treating GBM subjects, whereby the methods include (1) identifying the subject as a likely responder to PD-1 blockade, and (2) administering a PD-1 inhibitor and/or a programmed death-ligand 1 (PD-L1) inhibitor.

公开(公告)号：US20230364046A1

公开(公告)日：2023-11-16

申请号：US18223810

申请日：2023-07-19

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Andong QIU ,  Andrew BEENKEN ,  Jonathan BARASCH

IPC: A61K31/198 ,  A61K31/4172 ,  A61K9/00 ,  A61P13/12

CPC classification number: A61K31/198 ,  A61K31/4172 ,  A61K9/0019 ,  A61P13/12

Abstract: The subject method described herein relates to a method of treating, preventing, or reducing the incidence of Acute Kidney Injury (AKI) in a subject in need thereof by administering to the subject a pharmaceutically effective amount of one or more amino acids.

公开(公告)号：US20230344907A1

公开(公告)日：2023-10-26

申请号：US18137734

申请日：2023-04-21

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Baihan Lin

IPC: H04L67/133 ,  G06F16/25 ,  G06F9/54 ,  G06N3/092 ,  G06F3/01

CPC classification number: H04L67/133 ,  G06F16/258 ,  G06F9/547 ,  G06F9/546 ,  G06N3/092 ,  G06F3/015

Abstract: Disclosed are methods, systems, and other implementations for processing and managing high volume complex data (such as captured neural signals data). The implementations include a method that includes receiving at a first network device, from a remote, second network device, a remote procedure call (RPC) message comprising a first data representation of neural signal data obtained by the second network device and servicing data specifying parameters to cause execution of a first servicing procedure executable on the first network device, performing the first servicing procedure to process the first data representation of the neural signal data to generate result data, and transmitting, by the first remote network device, another RPC message to a destination network device, the other RPC message including the result data.

公开(公告)号：US20230340129A1

公开(公告)日：2023-10-26

申请号：US18335826

申请日：2023-06-15

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Benjamin IZAR ,  Johannes C. MELMS ,  Patricia HO

IPC: C07K16/28 ,  A61K38/17

CPC classification number: C07K16/2827 ,  A61K38/1774

Abstract: The method of enhancing anti-tumor immunity in a patient by targeting the CD58:CD2 axis uses an administered treatment to target and disrupt CMTM6 regulation of PD-L1 protein, thus enhancing the immune response and cancer immunotherapy in the patient. Targeting and disruption of CMTM6 regulation of the PD-L1 protein may be combined with additional prompting of a PD-1 blockage or adoptive cell transfer (ACT) in the patient. Targeting and disrupting CMTM6 regulation of PD-L1 protein may be initiated by administering an effective amount of antibodies to the patient, which are specific to disrupting CMTM6/PD-L1 protein interaction. Alternatively, to enhance the anti-tumor immunity in the patient, CD2 mediated signaling may be increased in order to stimulate an immune response. As another alternative to using antibodies or a CD58 mimetic, a pharmacological target to boost CD2/CD58 signaling in the patient may be identified and administered to enhance anti-tumor immunity.

公开(公告)号：US20230331780A1

公开(公告)日：2023-10-19

申请号：US18104105

申请日：2023-01-31

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Elizabeth Bradshaw ,  Wassim Elyaman

IPC: C07K7/08 ,  A61K45/06 ,  A61P25/28 ,  A61K47/54

CPC classification number: C07K7/08 ,  A61K45/06 ,  A61P25/28 ,  A61K47/54

Abstract: The present disclosure provides compositions and methods for disrupting the interaction of a siglec protein and its binding partners, and thereby treating neurodegenerative disease.

公开(公告)号：US20230330196A1

公开(公告)日：2023-10-19

申请号：US18310702

申请日：2023-05-02

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Suzanne Lentzsch ,  Shirong Li ,  Jing Fu ,  Markus Y. Mapara ,  Hui-Hui Ma

IPC: A61K38/48 ,  A61P37/06 ,  C12N9/64

CPC classification number: A61K38/4886 ,  A61P37/06 ,  C12N9/6424 ,  C12Y304/21

Abstract: Immunosuppressive peptide fragments of MMP-13, pharmaceutical compositions comprising said peptides, and methods of inhibiting T cell proliferation.